Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study.

Abstract

INTRODUCTION:

Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. Easy availability of this monoclonal antibody molecule even in Nepal has brought a revolution in the management of various retinal diseases. This study aims to find out the prevalence of the use of intravitreal Bevacizumab for retinal diseases at the tertiary eye hospital.

METHODS:

This descriptive cross-sectional study was carried out in the retina department at a tertiary care hospital from January 2017 to December 2019 after obtaining ethical clearance from Nepal Health Research Council (Ref: 125/2020P). The sample size was calculated and the study enrolled all patients who received intravitreal Bevacizumab for retinal diseases using convenience sampling technique. Data were analyzed using Statistical Package for Social Science Version 21. Point estimate at 95% Confidence Interval was calculated, along with frequency and percentage for binary data.

RESULTS:

Out of 959 total surgical retinal interventions done 296 (30.86%) at 95% Confidence Interval (27.93-33.78) patients received intravitreal Bevacizumab. Out of total intravitreal Bevacizumab injections, 143 (36.7%) injections were given to retinal vein occlusions patients, 127 (32.6%) injections were given to diabetic retinopathy patients and 66 (17%) injections was given to age-related macular degeneration patients. Males 176 (59.5%) outnumbered the females 120 (40.5%) in receiving intravitreal Bevacizumab. Mean baseline Logarithm of the Minimal Angle of Resolution visual acuity, 1.1, improved to, 0.75, after 3 months of intravitreal Bevacizumab.

CONCLUSIONS:

Intravitreal Bevacizumab was one of the commonest retinal interventions used. Retinal vein occlusion, diabetic retinopathy, and age-related macular degeneration were the commonest retinal diseases needing intravitreal Bevacizumab.

• Authors: Arjun Shrestha, Rinkal Suwal, Rajan Shrestha, Barsha Suwal, Deepak Khadka
• Journal: JNMA; journal of the Nepal Medical Association (JNMA J Nepal Med Assoc) Vol. 59 Issue 241 Pg. 858-861 (Sep 11 2021) ISSN: 1815-672X [Electronic] Nepal
• PMID: 35199738 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Angiogenesis Inhibitors (adverse effects)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab (therapeutic use)
• Cross-Sectional Studies
• Female
• Humans
• Intravitreal Injections
• Macular Edema (chemically induced, drug therapy)
• Male
• Retina
• Tertiary Care Centers
• Tomography, Optical Coherence
• Treatment Outcome
• Vascular Endothelial Growth Factor A (therapeutic use)